NEXGEL, Inc. (NXGL)
NASDAQ: NXGL · IEX Real-Time Price · USD
2.070
-0.030 (-1.43%)
At close: Jul 19, 2024, 4:30 PM
2.010
-0.060 (-2.90%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
NEXGEL Revenue
NEXGEL had revenue of $4.74M in the twelve months ending March 31, 2024, with 108.36% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.27M with 104.19% year-over-year growth. In the year 2023, NEXGEL had annual revenue of $4.09M with 99.66% growth.
Revenue (ttm)
$4.74M
Revenue Growth
+108.36%
P/S Ratio
2.72
Revenue / Employee
$249,263
Employees
19
Market Cap
12.89M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4.09M | 2.04M | 99.66% |
| Dec 31, 2022 | 2.05M | 497.00K | 32.04% |
| Dec 31, 2021 | 1.55M | 877.00K | 130.12% |
| Dec 31, 2020 | 674.00K | -43.00K | -6.00% |
| Dec 31, 2019 | 717.00K | -1.50M | -67.60% |
| Dec 31, 2018 | 2.21M | 221.00K | 11.09% |
| Dec 31, 2017 | 1.99M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| STRATA Skin Sciences | 32.55M |
| Novo Integrated Sciences | 13.66M |
| Guardion Health Sciences | 12.06M |
| Addex Therapeutics | 1.57M |
| Avalo Therapeutics | 1.45M |
| QT Imaging Holdings | 1.40M |
NXGL News
- 3 days ago - NEXGEL and Innovative Optics US Initiate Institutional Review Board (IRB) Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal - GlobeNewsWire
- 13 days ago - NEXGEL Announces Preliminary Record Second Quarter 2024 Revenue of $1.4 Million and Issues Revenue Guidance for Third and Fourth Quarter of 2024 of $2.2 Million and $2.6 Million, Respectively - GlobeNewsWire
- 5 weeks ago - NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America - GlobeNewsWire
- 2 months ago - NEXGEL Acquires International Beauty Brand, Silly George - GlobeNewsWire
- 4 months ago - NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year - GlobeNewsWire
- 4 months ago - NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday - GlobeNewsWire
- 4 months ago - NEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28th - GlobeNewsWire
- 4 months ago - NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th - GlobeNewsWire